26EHSKWCLMBLGLCRBTRGA: Fee-for-Service Claims for Blood Glucose Test Strips

The Massachusetts Executive Office of Health and Human Services (EOHHS) is issuing a solicitation to establish rebate agreements with manufacturers of blood glucose test strips, due to the expiration of existing rebate arrangements. The contract, titled "Fee-for-Service Claims for Blood Glucose Test Strips," aims to secure cost-effective access to diabetes testing supplies for MassHealth members, Health Safety Net patients, and those enrolled with participating managed care entities. The initial term begins January 1, 2026, for 24 months, with options for extensions up to three additional years. The agreement emphasizes fixed Guaranteed Net Unit Prices (GNUP) per National Drug Code (NDC), with rebate payments based on actual pharmacy claims processed through fee-for-service and managed care claims. Manufacturers must submit a fully completed State Rebate Agreement and Attachment A, detailing proposed prices for each NDC, along with a cover letter outlining transition strategies, customer support plans, and relevant experience. The evaluation process employs a best value approach, considering responsiveness, experience, price, and added value, with no mandatory lowest bid requirement. The contract incorporates specific clauses governing amendments, scope modifications, confidentiality, audit rights, and compliance with applicable laws, all governed by Massachusetts law. Administrative procedures specify quarterly rebate payments, record retention for seven years, and audit rights for state and federal agencies, with no explicit federal FAR clauses incorporated. Delivery performance is structured around the contract period, with products supplied via pharmacies, and no detailed shipping or acceptance standards are specified. The solicitation deadline is October 3, 2025, and proposals must be submitted through COMMBUYS or via email, with signatures accepted in ink or electronic formats. Overall, the contract emphasizes administrative compliance, price transparency, and flexibility to adapt to policy changes, ensuring continued access to vital diabetes testing supplies for eligible Massachusetts residents.